Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02828592 · ClinicalTrials.gov registry record · Phase 2
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
A Phase 2 study of Severe Aplastic Anemia, sponsored by Northside Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT02828592 is a Phase 2 study of Severe Aplastic Anemia that is actively recruiting participants, run by Northside Hospital. The registered enrollment target is 20 participants, below the 125-participant average among 16 other Severe Aplastic Anemia trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02828592, a Phase 2 study of Severe Aplastic Anemia, is actively recruiting participants, sponsored by Northside Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3 relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical donor for transplantation has good response rates and significantly lower rates of acute and chronic GVHD.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- RADIATION Total Body Irradiation
- DRUG Rabbit ATG
Study Locations (2)
Georgia
- Blood and Marrow Transplant Group of Georgia - Atlanta
- Northside Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-09-09 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02828592
The ClinicalTrials.gov registry entry for NCT02828592 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 125-participant average among 16 other Severe Aplastic Anemia trials with a reported enrollment target (84% lower). The listed sponsor is Northside Hospital, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Aplastic Anemia appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02828592 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02828592 about?
NCT02828592 is a clinical study titled "Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia". Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a respon...
What is the current status of trial NCT02828592?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-09-09. Estimated completion is 2027-08-31.
What conditions does trial NCT02828592 study?
This clinical trial studies the following conditions: Severe Aplastic Anemia.
What interventions are being tested in trial NCT02828592?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Total Body Irradiation (RADIATION), Rabbit ATG (DRUG).
Who is sponsoring clinical trial NCT02828592?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02828592 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Aplastic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
RECRUITING · Phase 2
-
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
RECRUITING · Phase 2
-
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
RECRUITING · Phase 2
-
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
RECRUITING · Phase 2
-
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.